A Single-centre, Open-label, Randomised, Crossover, Drug-drug Interaction Study to Investigate the Effect of a Single Oral Dose of Ritonavir on the Single Dose Pharmacokinetics of ASP2151 in Healthy Men

Maruho Europe Limited1 个研究点分布在 1 个国家目标入组 48 人开始时间: 2014年9月最近更新: 2019年2月27日

适应症

干预措施

试验速览

阶段: 1 期
状态: 已完成
发起方
入组人数: 48
试验地点: 1
主要终点: Apparent Total Body Clearance (CL/F) of ASP2151 From Plasma

研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

ASP2151 is an experimental treatment for herpes. HIV infected people are susceptible to contracting other infections because of their compromised immune system. As HIV patients will be taking drugs to treat the virus this study aims to see if ASP2151 would interact with one of the drugs that is commonly prescribed to HIV patients (ritonavir).

研究设计

研究类型: Interventional
分配方式: Randomized
干预模型: Crossover
主要目的: Other
盲法: None

入排标准

年龄范围: 18 Years 至 45 Years（Adult）
性别: Male
接受健康志愿者: 是

入选标准

•Healthy volunteers
•Sufficient intelligence to understand the nature of the trial and any hazards of participating in it. Ability to communicate satisfactorily with the investigator and to participate in, and comply with the requirements of, the entire trial.
•Willingness to give written consent to participate after reading the information and consent form, and after having the opportunity to discuss the trial with the investigator or his delegate.

排除标准

•Clinically relevant abnormal history, physical findings, ECG, or laboratory values at the pre-trial screening assessment that could interfere with the objectives of the trial or the safety of the volunteer.
•Any of the following liver function tests higher than 1.5 times the ULN at the screening visit: aspartate aminotransferase (AST), alanine aminotransferase (ALT), ALP, bilirubin, gamma glutamyl transpeptidase (gamma-GT).
•Platelet counts outside normal limits.
•Presence of acute or chronic illness or history of chronic illness sufficient to invalidate the volunteer's participation in the trial or make it unnecessarily hazardous.
•Clinically significant impaired endocrine, thyroid, hepatic, respiratory or renal function, diabetes mellitus, coronary heart disease, or history of any psychotic mental illness.
•History of bleeding diathesis.
•Surgery (eg stomach bypass) or medical condition that might affect absorption of medicines.
•Presence or history of severe adverse reaction to any drug, history of multiple drug allergies (multiple defined as >3), or sensitivity to trial medication.
•Use, during the 28 days before the first dose of trial medication, of any prescription medicine, or any other medicine or herbal remedy (such as St John's wort) known to interfere with the CYP3A4 metabolic pathway (unless judged as not clinical significant by the investigator and sponsor).
•Use, during the 7 days before the first dose of trial medication, of any over-the-counter medicine, with the exception of paracetamol (acetaminophen).
•Participation in another clinical trial of a new chemical entity or a prescription medicine within the previous 3 months.
•Loss of more than 400 mL blood during the 3 months before the trial, eg as a blood donor.
•Presence or history of drug or alcohol abuse, or intake of more than 21 units of alcohol weekly or more than 10 cigarettes daily.
•Evidence of drug abuse on urine testing.
•Positive test for hepatitis B, hepatitis C, HIV1 or HIV
•Blood pressure (BP) and heart rate (HR) in seated position at the screening examination outside the ranges 90-140 mm Hg systolic, 40-90 mm Hg diastolic; heart rate 40_100 beats/min.

研究组 & 干预措施

400mg ASP2151

Other

400mg ASP2151 alone followed by 400mg ASP2151 + 600mg ritonavir

干预措施: ASP2151 (Drug)

400mg ASP2151

Other

400mg ASP2151 alone followed by 400mg ASP2151 + 600mg ritonavir

干预措施: ritonavir (Drug)

1200mg ASP2151

Other

1200mg ASP2151 alone followed by 1200mg ASP2151 + 600mg ritonavir

干预措施: ASP2151 (Drug)

1200mg ASP2151

Other

1200mg ASP2151 alone followed by 1200mg ASP2151 + 600mg ritonavir

干预措施: ritonavir (Drug)